①Tantan's net profit in 2025 exceeded 1.5 billion yuan, what is the year-on-year increase compared to the previous year? ②Huaying Construction's subsidiary won a 3.6 billion Hong Kong dollar engineering project. What are the details?
Cailian Press, March 9 (Editor: Feng Yi) Cailian Press brings you today’s key announcements for Hong Kong stocks.
1) Corporate News
Huaying Construction (01582.HK): Subsidiary won a major construction contract involving a logistics center development project in Kwai Chung, New Territories, Hong Kong, worth 3.6 billion Hong Kong dollars.
Tantan (09890.HK): Expected net profit for 2025 will be no less than 1.5 billion yuan, compared to 44 million yuan in net profit in the same period last year.
Jiutai Bangda Energy (02798.HK): Estimated post-tax loss of 178-218 million yuan in 2025, compared to a profit of 440 million yuan last year.
Southern Manganese (01091.HK): Expected to turn losses into profits in 2025, with net profit of no less than 140 million Hong Kong dollars.
Hutchison Telecommunications Hong Kong (00215.HK): Revenue for 2025 reached 5.448 billion Hong Kong dollars, up 17% year-on-year; net loss of 25 million Hong Kong dollars, turning from profit to loss year-on-year.
Chinese Estates (00127.HK): Revenue for fiscal year 2025 was 301 million Hong Kong dollars, down 10.61% year-on-year; loss of 388 million Hong Kong dollars, narrowing by 81.57% year-on-year.
Jiali Trading Treasure (08017.HK): Added 7 institutional customers in February, an increase of 6 compared to the same period last year; registered users reached 893,000, up 5.9% year-on-year; Daxinji users reached 115,000, up 8.4% year-on-year.
Hopson Development Holdings (01813.HK): Contract sales in February amounted to 250 million yuan, down 30.7% year-on-year.
Hengrui Pharma (01276.HK): The HRS9531 injection has received clinical trial approval, with cumulative R&D investment in related projects amounting to approximately RMB 632 million.
Henlius (02696.HK): The Investigational New Drug (IND) application for the Phase 1 clinical trial of HLX316 injection (a sialidase Fc fusion protein targeting B7-H3) in patients with advanced/metastatic solid tumors has been approved by the National Medical Products Administration (NMPA).
Harbour BioMed-B (02142.HK): The IND application for HBM7575, intended for the treatment of atopic dermatitis, has been approved by the NMPA.
Coastal Home (01124.HK): The seller and the offeror are still in negotiations.
Lingbao Gold (03330.HK): Its H shares have been included in the list of eligible securities for Stock Connect.
Pharmaron-B (02617.HK): Included as a constituent stock in the Hang Seng Index series.
2) Share Repurchase Updates
Geely Auto (00175.HK): Repurchased 735,000 shares at a cost of HKD 11.29 million, with repurchase prices ranging from HKD 15.26 to HKD 15.60 per share.
Xindong Co. (02400.HK): Repurchased 112,000 shares at a cost of HKD 7.88 million, with repurchase prices ranging from HKD 68.25 to HKD 71.95 per share.
Yidu Tech (02158.HK): Repurchased 1,404,700 shares at a cost of HKD 8.10 million, with repurchase prices ranging from HKD 5.68 to HKD 5.83 per share.
